493 reports of this reaction
1.4% of all ZIPRASIDONE HYDROCHLORIDE reports
#20 most reported adverse reaction
OBESITY is the #20 most commonly reported adverse reaction for ZIPRASIDONE HYDROCHLORIDE, manufactured by ROERIG. There are 493 FDA adverse event reports linking ZIPRASIDONE HYDROCHLORIDE to OBESITY. This represents approximately 1.4% of all 35,561 adverse event reports for this drug.
ZIPRASIDONE HYDROCHLORIDE has an overall safety score of 82 out of 100. Patients taking ZIPRASIDONE HYDROCHLORIDE who experience obesity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OBESITY is a less commonly reported adverse event for ZIPRASIDONE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to obesity, the following adverse reactions have been reported for ZIPRASIDONE HYDROCHLORIDE:
The following drugs have also been linked to obesity in FDA adverse event reports:
OBESITY has been reported as an adverse event in 493 FDA reports for ZIPRASIDONE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OBESITY accounts for approximately 1.4% of all adverse event reports for ZIPRASIDONE HYDROCHLORIDE, making it a notable side effect.
If you experience obesity while taking ZIPRASIDONE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.